These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 31456101)

  • 1. Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel.
    Man YN; Chen YF
    Int Urol Nephrol; 2019 Dec; 51(12):2189-2199. PubMed ID: 31456101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.
    Buttigliero C; Pisano C; Tucci M; Vignani F; Bertaglia V; Iaconis D; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
    Acta Oncol; 2017 Apr; 56(4):555-562. PubMed ID: 28068151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.
    Lolli C; Caffo O; Scarpi E; Aieta M; Conteduca V; Maines F; Bianchi E; Massari F; Veccia A; Chiuri VE; Facchini G; De Giorgi U
    Front Pharmacol; 2016; 7():376. PubMed ID: 27790145
    [No Abstract]   [Full Text] [Related]  

  • 4. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.
    Nuhn P; Vaghasia AM; Goyal J; Zhou XC; Carducci MA; Eisenberger MA; Antonarakis ES
    BJU Int; 2014 Dec; 114(6b):E11-E17. PubMed ID: 24529213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617.
    Şahin E; Kefeli U; Zorlu Ş; Seyyar M; Ozkorkmaz Akdag M; Can Sanci P; Karakayali A; Ucuncu Kefeli A; Bakkal Temi Y; Cabuk D; Uygun K
    Medicine (Baltimore); 2023 Nov; 102(47):e35843. PubMed ID: 38013293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients.
    Kobayashi H; Shiota M; Sato N; Kobayashi S; Matsumoto T; Monji K; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
    Anticancer Drugs; 2022 Jan; 33(1):e541-e547. PubMed ID: 34387597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients.
    Stangl-Kremser J; Mari A; Suarez-Ibarrola R; D'Andrea D; Korn SM; Pones M; Kramer G; Karakiewicz P; Enikeev DV; Glybochko PV; Briganti A; Shariat SF
    Urol Oncol; 2020 Jun; 38(6):600.e9-600.e15. PubMed ID: 31953003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
    Sonpavde G; Pond GR; Armstrong AJ; Clarke SJ; Vardy JL; Templeton AJ; Wang SL; Paolini J; Chen I; Chow-Maneval E; Lechuga M; Smith MR; Michaelson MD
    Clin Genitourin Cancer; 2014 Oct; 12(5):317-24. PubMed ID: 24806399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of neutrophil-to-lymphocyte ratio in castration resistant prostate cancer: Single-centre study of Nigerian men.
    Bello JO; Olanipekun OO; Babata AL
    Niger J Clin Pract; 2019 Apr; 22(4):511-515. PubMed ID: 30975955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
    Wang Z; Liu H; Zhu Q; Chen J; Zhao J; Zeng H
    BMC Cancer; 2024 Jul; 24(1):817. PubMed ID: 38978000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China.
    Pei XQ; He DL; Tian G; Lv W; Jiang YM; Wu DP; Fan JH; Wu KJ
    Int Urol Nephrol; 2017 Apr; 49(4):629-635. PubMed ID: 28161841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
    Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
    Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy.
    Yamashita S; Kohjimoto Y; Iguchi T; Koike H; Kusumoto H; Iba A; Kikkawa K; Kodama Y; Matsumura N; Hara I
    BMC Urol; 2016 Mar; 16():13. PubMed ID: 27001073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.
    Wu KJ; Pei XQ; Tian G; Wu DP; Fan JH; Jiang YM; He DL
    Asian J Androl; 2018; 20(2):173-177. PubMed ID: 28905815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.
    Boegemann M; Schlack K; Thomes S; Steinestel J; Rahbar K; Semjonow A; Schrader AJ; Aringer M; Krabbe LM
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
    Linton A; Pond G; Clarke S; Vardy J; Galsky M; Sonpavde G
    Clin Genitourin Cancer; 2013 Dec; 11(4):423-30. PubMed ID: 23816526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory markers as prognostic factors in metastatic castration-resistant prostate cancer.
    Donate-Moreno MJ; Lorenzo-Sánchez MV; Díaz de Mera-Sánchez Migallón I; Herraiz-Raya L; Esper-Rueda JA; Legido-Gómez O; Rico-Marco S; Salinas-Sánchez AS
    Actas Urol Esp (Engl Ed); 2020 Dec; 44(10):692-700. PubMed ID: 33010988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort.
    Neuberger M; Goly N; Skladny J; Milczynski V; Weiß C; Wessels F; Nitschke K; Grüne B; Haney CM; Hartung F; Herrmann J; Jarczyk J; Kowalewski KF; Waldbillig F; Kriegmair MC; Westhoff N; Worst TS; Nuhn P
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3371-3381. PubMed ID: 35939112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs.
    Deng C; Zhang N; Wang Y; Jiang S; Lu M; Huang Y; Ma J; Hu C; Hou T
    Medicine (Baltimore); 2019 Aug; 98(33):e16875. PubMed ID: 31415428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer.
    Lozano Martínez AJ; Moreno Cano R; Escobar Páramo S; Salguero Aguilar R; Gonzalez Billalabeitia E; García Fernández R; De La Fuente Muñoz I; Romero Borque A; Porras Martínez M; Lopez Soler F; Cardenas Cánovas E; Ortega Martín I
    Clin Transl Oncol; 2017 Dec; 19(12):1531-1536. PubMed ID: 28718070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.